W. Mcguire

发表

Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.

T. Conrads, D. Sidransky, B. Hood, 2015, Journal of proteome research.

Taste thresholds of patients with cancer of the esophagus

T. Lad, W. Mcguire, S. Kamath, 1983, Cancer.

Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer

J. Berek, W. Mcguire, J. Blessing, 1990, Investigational New Drugs.

Ovarian cancer: screening, treatment, and followup.

Robert C. Bast, Robert W. Makuch, Alice S. Whittemore, 1995, NIH consensus statement.

Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A. Iasonos, P. Sabbatini, K. Odunsi, 2006, Clinical Cancer Research.

Sequences of taxol and cisplatin: a phase I and pharmacologic study.

E K Rowinsky, L. Grochow, D. Ettinger, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.

R. Ozols, J. Walczak, R. Alvarez, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel in cancer treatment

E. Rowinsky, W. Mcguire, 1995 .

Successful re-treatment with taxol after major hypersensitivity reactions.

M. Piccart, E. Eisenhauer, L. Gianni, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of pemetrexed with sorafenib in advanced solid tumors

John D. Roberts, C. Geyer, P. Dent, 2016, Oncotarget.

Recurrent ovarian cancer.

W. Mcguire, M. Tummala, 2005, Clinical advances in hematology & oncology : H&O.

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.

D. Ettinger, R. Donehower, E. Rowinsky, 1989 .

[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling

P. Dent, A. Koromilas, D. Boone, 2016, Oncotarget.

Camptothecin analogues/cisplatin: an effective treatment of advanced bladder cancer in a preclinical in vivo model system.

J. Petros, W. Mcguire, T. Keane, 1998, The Journal of urology.

The treatment of epithelial ovarian cancer

W. Mcguire, F. Qazi, Faridullah Qazi, 1995, CA: a cancer journal for clinicians.

Synchronous mature teratomas of the ovary and liver: a case presenting 11 years following chemotherapy for immature teratoma.

C. Caldas, W. Mcguire, J. Sitzmann, 1992, Gynecologic oncology.

Maintenance therapy for ovarian cancer: of Helsinki and Hippocrates.

W. Mcguire, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study.

G. Sutton, W. Mcguire, J. Blessing, 1993, American journal of obstetrics and gynecology.

L. Kang, S. Temkin, W. Mcguire, 2018, International Journal of Gynecologic Cancer.

Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS

P. Dent, W. Mcguire, L. Booth, 2016, Oncotarget.

Methodology phase II clinical trial in cancer.

M. Staquet, F. Muggia, M. Rozencweig, 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Is it time for some new approaches for treating advanced ovarian cancer?

W. Mcguire, 2006, Journal of the National Cancer Institute.

Advanced epithelial ovarian cancer: 1998 consensus statements.

M. Parmar, E. Eisenhauer, M. Gore, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

E. Partridge, M. Brady, W. Hoskins, 1996, New England Journal of Medicine.

CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers

R. Ozols, D. Spriggs, R. Zaino, 2009, Cancer.

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer.

J. Berek, P. Taylor, W. Mcguire, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intraperitoneal chemotherapy: standard of care for patients with minimal residual stage III ovarian cancer?

W. Mcguire, M. Tummala, S. Alagarsamy, 2008, Expert review of anticancer therapy.

Progress in the Management of Gynecologic Cancer

S. Cannistra, W. Mcguire, 2007 .

A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.

J. Schilder, R. Bristow, D. Armstrong, 2007, Gynecologic oncology.

Current status of taxane and platinum-based chemotherapy in ovarian cancer.

W. Mcguire, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2003, International Journal of Gynecologic Cancer.

Chemotherapy for advanced epithelial ovarian carcinoma.

W. Mcguire, N. Kalil, 2002, Best practice & research. Clinical obstetrics & gynaecology.

Contemporary management of ovarian cancer.

W. Mcguire, N. Rosenshein, D. D. Im, 2001, Obstetrics and gynecology clinics of North America.

Intraperitoneal therapy for ovarian cancer: a sacrifice bunt.

W. Mcguire, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.

S. Waggoner, P. Rose, I. Horowitz, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Confirmation of the "old" standard of care for ovarian cancer and a challenge.

W. Mcguire, 2000, Journal of the National Cancer Institute.

The Gynecologic Oncology Group experience in ovarian cancer.

R. Ozols, M. Brady, W. Mcguire, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.

P. Rose, I. Horowitz, W. Mcguire, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination paclitaxel (Taxol®)–cisplatin vs cyclophosphamide–cisplatin as primary therapy in patients with suboptimally debulked advanced ovarian cancer

E. Partridge, M. Brady, W. Hoskins, 1997 .

Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group.

R. Ozols, P. O'dwyer, S. Johnson, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma.

W. Mcguire, 1993, Gynecologic oncology.

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

M. Gore, R. Ilaria, R. Penson, 2018, BMC Cancer.

Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia

R. Donehower, E. Rowinsky, W. Mcguire, 1995, Cancer Chemotherapy and Pharmacology.

Ovarian cancer and antiangiogenic therapy: caveat emptor.

W. Mcguire, K. Oliver, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy of lung cancer

F. Muggia, W. Mcguire, S. Mikulski, 1979 .

Phase I Trial of Paclitaxel and Etoposide for Recurrent Ovarian Carcinoma: A Gynecologic Oncology Group Study

P. Fracasso, S. Baker, G. Sutton, 2000, American journal of clinical oncology.

Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine

D. Ball, S. Averbuch, W. Mcguire, 1994, Cancer.

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

E. Partridge, M. Brady, W. Hoskins, 1996, The New England journal of medicine.

Clear Cell Carcinoma of the Ovary: A Remarkable Case

M. Fanucchi, W. Mcguire, J. Giblin, 2001, American journal of clinical oncology.

Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis.

S. Vadhan-Raj, W. Mcguire, D. Tomita, 2002, Oncology.

Advanced epithelial ovarian cancer

M. Parmar, E. Eisenhauer, M. Gore, 1999 .

Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study.

W. Mcguire, S. Lentz, J. Blessing, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective evaluation of front-line chemo-immunotherapy (C-IT) with oregovomab (2 alternative dosing schedules) carboplatin-paclitaxel (C-P) in advanced ovarian cancer (OC)

M. Method, R. Edwards, W. Mcguire, 2007 .

Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.

P. Fracasso, S. Waggoner, G. Sutton, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immediate versus postponed combination chemotherapy (CAMP) for unresectable non-small cell lung cancer: a randomized trial.

T. Lad, W. Mcguire, R. Nelson, 1981, Cancer treatment reports.

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Howard Mackey, R. Burger, R. Wenham, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon.

J. Berek, M. Markman, W. Mcguire, 1992, Gynecologic oncology.

Aminothiadiazole (NSC 4728) in Patients with Advanced Carcinoma of the Endometrium: A Phase II Study of the Gynecologic Oncology Group

R. Mortel, W. Mcguire, P. Hanjani, 1990, American journal of clinical oncology.

Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).

E. Partridge, M. Brady, W. Hoskins, 1996, Seminars in oncology.

The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience.

M. Brady, W. Hoskins, R. Vance, 1995, Seminars in oncology.

Another confirmation of the inactivity of topotecan in ovarian cancer.

W. Mcguire, 2010, Journal of the National Cancer Institute.

CLINICAL STATUS AND OPTIMAL USE OF TOPOTECAN

W. Mcguire, 1997 .

Bevacizumab in patients with advanced platinum-resistant ovarian cancer.

R. Burger, R. Wenham, S. Cannistra, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of acivicin in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.

P. Disaia, W. Mcguire, J. Blessing, 1986, Investigational new drugs.

Reply to T.j. Herzog et Al.

W. Mcguire, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of ifosfamide and mesna in nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group study.

P. Disaia, G. Sutton, W. Mcguire, 1993, Gynecologic oncology.

A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.

Joan L. Walker, P. Rose, W. Mcguire, 2002, Gynecologic oncology.

Ovarian cancer, CA-125 addiction, and informed confusion: much ado about less.

W. Mcguire, M. Tummala, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Salvage therapy in epithelial ovarian cancer.

C. Caldas, W. Mcguire, L. E. Morris, 1994, Obstetrics and gynecology clinics of North America.

Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evalua...

R. Mannel, M. Brady, M. Pearl, 2010 .

Primary treatment of epithelial ovarian malignancies

W. Mcguire, 1993, Cancer.

Old drugs revisited, new drugs, and experimental approaches in ovarian cancer therapy.

E. Rowinsky, W. Mcguire, 1991, Seminars in oncology.

Paclitaxel (Taxol) therapy in ovarian carcinoma.

C. Caldas, W. Mcguire, 1993, Seminars in oncology.

A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer.

W. Hauck, S. Taylor, T. Lad, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary culture of squamous head and neck cancer with and without 3T3 fibroblasts and effect of clinical tumor characteristics on growth in vitro

M. Cobleigh, E. Applebaum, W. Mcguire, 1987, Cancer.

Pharmacologic, Pre-clinical and Clinical Investigations of the Cisplatin/Taxol Combination

M. Gilbert, M. Citardi, D. Noe, 1991 .

Cardiac candidiasis in cancer patients

W. Roberts, H. Brereton, A. Levine, 1978, Cancer.

Bleomycin-lnduced Raynaud's Phenomenon

W. Mcguire, L. Bressler, L. Kukla, 1981 .

Surgical management of peritoneal carcinomatosis in ovarian cancer

R. Rouzier, S. Memarzadeh, J. Berek, 2014 .

PROGNOSTIC VALUE OF PRETREATMENT CA-125 IN ADVANCED OVARIAN CARCINOMA: A GYNECOLOGIC ONCOLOGY GROUP STUDY

R. Ozols, D. Spriggs, P. Rose, 2009 .

Age as a prognostic factor in ovarian carcinoma: The gynecologic oncology group experience

M. Brady, W. Creasman, S. Williams, 2010, Cancer.

Ovarian Cancer in the Elderly: Further Considerations

W. Mcguire, 2008 .

Carboplatin substitution for cisplatin in the treatment of ovarian carcinoma--a word of caution.

W. Mcguire, M. Abeloff, 1989, Journal of the National Cancer Institute.

Gynecologic Oncology Group studies with ifosfamide.

G. Sutton, W. Mcguire, H. Homesley, 1992, Seminars in oncology.

Acute vascular episodes associated with therapy for carcinomas of the upper aerodigestive tract with bleomycin, vincristine, and cisplatin.

T. Lad, W. Mcguire, L. Kukla, 1982, Cancer treatment reports.

Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study.

L. Grochow, D. Ettinger, D. Noe, 1987, Cancer research.

Ovarian Cancer: Controversies in Management

D. Gershenson, W. Mcguire, 1997 .

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

R. Ozols, P. Rose, F. Muggia, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapeutic approaches to ovarian cancer management.

W. Mcguire, 2000, Seminars in oncology.

Gynecologic Cancer: Controversies in Management

M. Gore, M. Quinn, D. Gershenson, 2004 .

Progress in the management of gynecologic cancer: consensus summary statement.

R. Bast, S. Skates, J. Garber, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

L. Grochow, D. Ettinger, C. Hendricks, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.

J. Berek, M. Brady, W. Creasman, 1994, American journal of obstetrics and gynecology.

A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.

P. Disaia, K. Hatch, N. Teng, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiac disturbances during the administration of taxol.

E K Rowinsky, M. Christian, T. Guarnieri, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma.

E. Chang, W. Koch, W. Mcguire, 1990, Archives of otolaryngology--head & neck surgery.

Pancreatic polypeptide hypersecretion associated with a neuroendocrine carcinoma of the gallbladder.

W. Mcguire, A. Gal, L. Blevins, 1999, The American journal of the medical sciences.

Early side effects of intrathoracic BCG therapy in patients with stage I squamous cell carcinoma, adenocarcinoma, or large cell lung cancer

M. Gail, C. Mountain, E. Holmes, 1981, Cancer Immunology, Immunotherapy.

Adjuvant Therapy with Surgery: Immunotherapy — Overview

W. Mcguire, 1981 .

Immunotherapy of lung cancer. I. Review of clinical trials in non-small cell histologic types.

F. Muggia, W. Mcguire, S. Mikulski, 1979, Cancer treatment reviews.

Phase II trial of acivivin in patients with advanced epithelial ovarian carcinoma

P. Disaia, W. Mcguire, J. Blessing, 2004, Investigational New Drugs.

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

D. Alberts, R. Burger, E. Trimble, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.

D. Alberts, D. Bodurka, U. Matulonis, 2006, Gynecologic oncology.

Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.

M. Birrer, R. Dickson, K. Darcy, 2009, Gynecologic oncology.

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.

P. Thaker, R. Coleman, W. Mcguire, 2015, Gynecologic oncology.

HE4--another marker for gynecologic cancers: do we really need one?

W. Mcguire, 2013, Oncology.

Primary ovarian cancer chemotherapy: current standards of care

M. Markman, W. Mcguire, WP McGuire, 2003, British Journal of Cancer.

Radiation Treatment in Women with Ovarian Cancer: Past, Present, and Future

S. Temkin, W. Mcguire, E. Fields, 2017, Front. Oncol..

Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel.

M. Gore, G. Rustin, J. Bridgewater, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.

S. Rubin, P. Rose, F. Muggia, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Immune Adjuvant Properties of Front-line Carboplatin-Paclitaxel: A Randomized Phase 2 Study of Alternative Schedules of Intravenous Oregovomab Chemoimmunotherapy in Advanced Ovarian Cancer

T. Whiteside, M. Method, R. Edwards, 2009, Journal of immunotherapy.

Endometrial adenocarcinoma following endometrial ablation for postmenopausal bleeding.

I. Horowitz, W. Mcguire, C. Spann, 1995, Gynecologic oncology.

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125.

H E Lambert, G. Rustin, G. Rustin, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

C. Dunton, M. Bookman, W. Mcguire, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

T. Grogan, P. Fracasso, M. Brady, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and Pharmacokinetic Study of Hepsulfam ( NSC 329680 ) 1

L. Grochow, D. Ettinger, C. Hendricks, 2006 .

Phase I and pharmacokinetic study of hepsulfam (NSC 329680).

L. Grochow, D. Ettinger, C. Hendricks, 1991, Cancer research.

Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients

J. Verweij, S. Clarke, M. Carducci, 2004, Clinical Cancer Research.

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study.

J. Berek, M. Brady, W. Creasman, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

D. Matei, A. Oza, D. Provencher, 2019, Clinical Cancer Research.

Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma

John D. Roberts, P. Dent, R. Sterling, 2019, American journal of clinical oncology.

Anaphylaxis to carboplatin--a new platinum chemotherapeutic agent.

N. Adkinson, W. Mcguire, R. Hamilton, 1992, The Journal of allergy and clinical immunology.

The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling

P. Dent, W. Mcguire, Jane L. Roberts, 2016, Oncotarget.

Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line

T. Conrads, D. Sidransky, B. Hood, 2017, Human Cell.

Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study.

M. Birrer, K. Darcy, C. Tian, 2009, Gynecologic oncology.

Liposomal anthracycline treatment for ovarian cancer.

F. Muggia, M. Markman, W. Mcguire, 2004, Seminars in oncology.

Extraovarian granulosa cell tumor.

W. Mcguire, N. Rosenshein, D. D. Im, 1999, Gynecologic oncology.

CASE REPORT Extraovarian Granulosa Cell Tumor

W. Mcguire, N. Rosenshein, D. D. Im, 1999 .

Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance

P. Dent, W. Mcguire, Jane L. Roberts, 2015, Cancer biology & therapy.

Sequential chemotherapy and immunotherapy for the treatment of metastatic melanoma.

E. Fishman, L. Schuchter, W. Mcguire, 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

High-dose chemotherapy and autologous bone marrow or stem cell reconstitution for solid tumors.

W. Mcguire, William P. McGuire, 1998, Current problems in cancer.

Preirradiation chemotherapy for advanced head and neck carcinomas.

E. Applebaum, W. Mcguire, R. Mantravadi, 1984, Archives of otolaryngology.

Phase II study of esorubicin (4′-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: A Gynecologic Oncology Group study

E. Yordan, W. Mcguire, J. Blessing, 1989, Investigational New Drugs.

Comparison of combination therapy with paclitaxel Taxol® and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study

E. Partridge, M. Brady, W. Hoskins, 1996, International Journal of Gynecologic Cancer.

Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.

D. Cella, S. Waggoner, T. Herzog, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hexamethylene bisacetamide-induced cutaneous vasculitis.

D. Ettinger, R. Donehower, E. Rowinsky, 1987, Cancer treatment reports.

Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.

L. Grochow, D. Ettinger, D. Noe, 1990, Cancer research.

Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics.

E K Rowinsky, L. Grochow, D. Ettinger, 1989, Journal of the National Cancer Institute.

Clinical and pharmacologic reappraisal of dichloromethotrexate.

L. Grochow, D. Ettinger, D. Noe, 1988, Journal of the National Cancer Institute.

R. Mannel, M. Brady, K. Darcy, 2010, Gynecologic oncology.

Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: a gynecologic oncology group study.

M. Birrer, M. Brady, K. Darcy, 2011, Gynecologic oncology.

Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.

D. Alberts, B. Monk, R. Burger, 2019, Gynecologic oncology.

Current Approaches and Challenges in Managing and Monitoring Treatment Response in Ovarian Cancer

K. Darcy, C. Hamilton, G. Maxwell, 2014, Journal of Cancer.

Take me to your leader: Reporting structures and equity in academic gynecologic oncology.

S. Temkin, U. Chandavarkar, B. Rimel, 2020, Gynecologic oncology.

Evaluation of CYP3A activity as a predictive covariate for docetaxel clearance.

J. Verweij, M. Carducci, H. Gelderblom, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Topotecan H as S ubstantial A ntitumor A ctivity a s F irst- Line S alvage T herapy i n P latinum-Sensiti ve E pithelial Ovarian C arcinoma: A G ynecologic O ncology G roup S tudy

C. Dunton, M. Bookman, W. Mcguire, 2000 .

Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers A Gynecologic Oncology Group study.

T. Bonome, K. Darcy, R. Young, 2008, Gynecologic oncology.

The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma

Maurie Markman, R. Ozols, D. Spriggs, 2009, Cancer.

Phase II study of Ifosfamide and Mesna in refractory adenocarcinoma of the endometrium

G. Sutton, W. Mcguire, H. Homesley, 1994, Cancer.

A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

A. Secord, G. Petroni, L. Duska, 2019, Gynecologic oncology.

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.

M. Gore, D. Bodurka, U. Matulonis, 2014, Gynecologic oncology.

Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia

R. Donehower, W. Slichenmyer, E. Rowinsky, 1995, Cancer Chemotherapy and Pharmacology.

Prospective monitoring for anthracycline cardiotoxicity: an introduction.

W. Mcguire, 1978, Cancer treatment reports.

M. Gore, R. Ilaria, R. Penson, 2018, BMC Cancer.

Impact of molecular profiling on overall survival of patients with advanced ovarian cancer

R. Burger, K. Burnett, M. Friedlander, 2016, Oncotarget.

Testis: A sanctuary site in merkel cell carcinoma

W. Mcguire, M. Tummala, P. Hausner, 2006 .

A model for malignancy-associated humoral hypercalcemia

S. Kukreja, T. Lad, W. Mcguire, 1984, Calcified Tissue International.

Long‐term follow‐up confirms a survival advantage of the paclitaxel–cisplatin regimen over the cyclophosphamide–cisplatin combination in advanced ovarian cancer

M. Piccart, K. Swenerton, I. Vergote, 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Endobronchial lesion from metastatic ovarian carcinoma resulting in partial right mainstem obstruction demonstrated by lung scintigraphy.

S. Sostre, W. Mcguire, M. Reinhardt, 1995, Clinical nuclear medicine.

Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer.

S. Arikian, J. Doyle, A. Neugut, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CA-125 and early ovarian cancer: does this help the clinician or further muddy the water?

W. Mcguire, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.

S. Vadhan-Raj, W. Mcguire, D. Tomita, 2003, The journal of supportive oncology.

Phase II study of esorubicin (4′-deozydoxorubicin) in advanced epithelial carcinoma of the ovary: A Gynecologic Oncology Group study

W. Mcguire, J. Blessing, M. Berman, 1989, Investigational New Drugs.

Assessing the effect of response on survival in ovarian cancer.

S. Piantadosi, W. Mcguire, 1992, Journal of the National Cancer Institute.